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Supplementary Note 
Differences in somatic and germline variant interpretation 
When considered in discovery and translational research endeavors, it is important to determine if a particular 
variant observed in a gene of interest is ​oncogenic​ (the variant functionally enables or predisposes towards the 
development of cancer), as this annotation provides the foundation on which targeted cancer treatment 
research is based. In contrast, clinical applications are dominated by diagnostic, prognostic, or therapeutic 
interpretations which in part also depends on underlying variant oncogenicity.  
The development of procedures for oncogenicity classification in somatic interpretation guidelines is an unmet 
need in the oncology domain. ClinGen, ACMG, AMP, ASCO, VICC and CAP are collaboratively developing 
such guidelines to enable consistent and comprehensive assessment of somatic variant oncogenicity. 
Consensus and recommendations for the elements of an Interpretation 
To provide readily searchable, standardized interpretations across knowledgebases, we evaluated the 
structure of cancer variant interpretations across the core dataset (​Figure 1​). Our first challenge was to 
develop a consensus for the minimum required data elements that constitute a cancer variant interpretation. 
These minimal elements include a gene identifier, variant name, cancer subtype (tumor type and organ), 
clinical implication (diagnostic, prognostic, therapeutic, or predisposing biomarker), provenance of supporting 
evidence (e.g., PubMed identifier), and curation source. In addition, we recommended ascribing a tiered level 
of support for the evidence contributing to the interpretation. Each VICC knowledgebase (​Supplementary 
Table 1​) provided cancer variant interpretations as structured data meeting these requirements.  
Difference in curation strategy 
The differing curation and data modeling strategies of these knowledgebases serve as contributing factors for 
their dramatically different variant content. CGI uses invited expert curators to build out its knowledgebase of 
therapeutic biomarkers. Similarly, JAX-CKB, MolecularMatch, OncoKB, and PMKB create interpretations from 
in-house expert panels, but the provenance of these interpretations are each credited to the entire panel 
instead of an individual curator. The CIViC knowledgebase provides an interface for anyone to curate cancer 
variant interpretations from the literature, and the curated content is then reviewed by expert editors. The need 
for only 1 (CGI) or 2 (CIViC) curators to generate interpretations may contribute to the greater breadth of 
variants in these resources compared to others. PMKB has far fewer variants than the others as a result of the 
way interpretations are modeled; many of the interpretations in PMKB apply to broad variant representations 
(described above as categorical variants) which may be used for multiple interpretations. In fact, there are 
more interpretations in PMKB than in OncoKB, but OncoKB has more specific variants associated with their 
interpretations. Additional differences exist between the focus of these knowledgebases that are not accounted 
for in our analysis. For instance, JAX-CKB and MolecularMatch each also aggregate clinical trial data, and CGI 
and OncoKB both maintain large “oncogenic” annotation lists, but none of these additional data are included in 
the analyses presented in this manuscript. 
Grouping of disease terms to top-level disease concepts 
The aggregated knowledge across the core dataset describes 357 distinct disease concepts from the Disease 
Ontology (DO)​47​ across 12,497 interpretations (​Supplementary Table 4​). These diseases range from highly 
specific (e.g. ​DOID:0080164 - myeloid and lymphoid neoplasms with eosinophilia and abnormalities of 
PDGFRA, PDGFRB, and FGFR1​) to generalized (e.g. ​DOID:162 - cancer​). To compare the variant 
interpretations to disease type, we used the expert-curated “TopNodeCancerSlim” DO mapping​50​ that 
describes 58 common, top-level disease terms (TopNode terms) across several major datasets, including The 
Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and COSMIC.​3,51,52  
Mapping GENIE diseases to Disease Ontology 
GENIE samples are annotated with a diverse array of Oncotree ontology (​oncotree.mskcc.org​) disease codes, 
with 81% (539 / 667) of Oncotree diseases represented in the dataset. Over 53% (286 / 539) of the Oncotree 
diseases from GENIE do not link to DO through cross-references, of which 34% (96 / 286) do not have any 
cross-references (​Supplementary​ ​Table 9​). This lack of cross-references among GENIE diseases is 
significantly higher than the 20% (133 / 667) of all Oncotree terms lacking cross-references (OR = 2.0, p = 
1.1e-5; Fisher’s exact test, two-sided), suggesting that terms used to describe individual patient cancers (e.g. 
Well-Differentiated Neuroendocrine Tumor of the Rectum​) are less likely to map to other knowledgebases than 
high-level parent terms (e.g. ​colorectal cancer​). Despite this, 65% of GENIE patients had a disease term map 
to DO, indicating that the common cancers among this cohort are more likely to be cross-referenced 
adequately for mapping. Further evaluation confirmed a significant enrichment of more frequently observed 
disease terms among the terms that mapped to DO, compared to those that did not (U = 31094.0, p = 4.8e-3; 
Mann-Whitney U test, two-sided; see ​Online Methods​). 
In addition to the above limitations, matching patient variants to diseases with our strategy is highly dependent 
upon ontology structure. For example, CGI exhibits a 54% reduction of exact matches due to the mapping of 
CGI terms to DO. To illustrate this problem, patients with DOID:3008, ​invasive ductal carcinoma​, account for 
11% of the unmatched diseases (or 6% of the overall reduction). 82% of these patients have a variant 
matching a CGI interpretation for DOID:3458, ​breast adenocarcinoma​. This is a sibling term to ​breast lobular 
carcinoma​ and ​breast ductal carcinoma​. As a result, GENIE ​invasive ductal carcinoma​ patients (​invasive ductal 
carcinoma​ is the sole descendant of ​breast ductal carcinoma​) do not match, as our match strategy requires 
ancestral relationships between concepts (see ​Extended Data Figure 4​ for details). 
Improvements from harmonization 
We observed large gains in overlapping terms between resources across variants, diseases, and drugs. 
Importantly, this harmonization allowed us to search relationships between patient and interpretation disease 
terms, improving precise matching between patient and interpretations of clinical significance. We noted that 
there was little need to harmonize gene identifiers, as each knowledgebase had independently selected HGNC 
gene symbols as a reference, enabling easy and direct comparison of genes. This underscores both the utility 
of standardized data, as well as the need for adoption of similar standards (such as those described in this 
work) to drive direct comparison of variant interpretations. In our analysis of the variants and diseases of the 
harmonized interpretations, we observed that frequent top-level cancer terms mirror cancers with high 
incidence and mortality. We also noted that a large percentage of these interpretations described a relatively 
small number of gene-disease relationships. 
Future goals 
Additionally, we are building inference tools to automatically identify the concepts users are querying in real 
time. We also will be expanding our effort to harmonize and present interpretations of various non-coding 
variants, structural variants beyond gene pairs, and aggregate markers like microsatellite instability status. A 
prioritized long-term goal is the development of standards and techniques for interpretations of combined 
germline and somatic variations. Similarly, we are building guidelines and methods to enable automated 
consensus recommendations. Finally, we are seeking out additional knowledgebases of clinical 
interpretations of variants to harmonize and share with the broader cancer genomics community, and building 
an API specification which they may use to incorporate their own interpretations. 
50. Wu, T.-J. et al. Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis. Database 2015, bav032 
(2015).
51. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core 
pathways. Nature 455, 1061–1068 (2008).
52. International Cancer Genome Consortium et al. International network of cancer genome projects. Nature 464, 993–998 (2010).
Participating Knowledgebase Agreement 
Dear VICC leaders, 
I would like to take this opportunity to express my commitment to participating in the Variant Interpretation for 
Cancer Consortium (VICC). As you know, we are one of several institutions engaged in the challenge of 
curating knowledge to annotate cancer genome mutations associated with evidence of pathogenicity or linked 
to relevant treatment options. Specifically, we have developed the [INSTITUTION RESOURCE (INSTITUTION 
NAME)]. While this resource serves the specific needs of our own institution, we recognize that there is ​clear 
value in sharing knowledge of cancer-variant-treatment associations.​ Such sharing will increase 
confidence where interpretations overlap, fill gaps, reduce redundancy, and leverage disparate domain 
expertise. To this end, we support your plans to coordinate global efforts for curation and help develop a 
community resource for cross-knowledgebase queries under the auspices of the Global Alliance for Genomics 
and Health (GA4GH). As a VICC participant we agree with the following data sharing principles, developed 
through community discussion at GA4GH meetings and calls.  
● We will commit to sharing at least a minimal set of data elements for cancer variant interpretations
including: gene symbol, variant name, cancer subtype (tumor type and organ), clinical implication (drug
sensitivity, drug resistance, adverse response, diagnostic, or prognostic), source (e.g., PubMed identifier)
and curation group.
● We agree that to avoid patient data privacy concerns, the project will focus on only clinical interpretations of
variants derived from published findings (literature, conference proceedings, and clinical trial records), not
individual patient/variant-level observations. Thus, there should be no possibility of linking variants to
individuals.
● We agree to share [SPECIFY: all OR a significant proportion] of our interpretations (with at least the
minimal required data elements) accumulated by our ongoing curation efforts.
● This content will be released under a permissive license (free and non-exclusive for at least research
use).
● Software developed as part of this data sharing initiative will be released in public repositories (e.g.,
github) with open source licenses.
● Public APIs will be developed to facilitate access to our data for use by the VICC.
● Wherever possible, data sharing will be facilitated by use of the existing GA4GH schemas, APIs and
demonstration implementations.
● Interpretations made available by our institution will also be made available as cross-knowledgebase
bulk downloads.
I look forward to working together with the Variant Interpretation for Cancer Consortium to further our common 
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Supplementary Equations 
Calculations for evaluating non-harmonized aggregate content 
Non-harmonized element counts: 
Given the set of interpretation elements:  
genes, variants, diseases, drugs}E = {     
and the set of knowledgebase resources: 
 {cgi, civic, jax, molecularmatch, oncokb, pmkb}R =        
For each element , and each resource , we created a unique set of ​non-harmonized​ element ∈ Ee  ∈ Rr  
values observed in that resource, .Se, r  
 
For ​genes​ ( ), we used HGNC gene symbols, which were provided by each knowledgebase.Sgenes, r ∈ R  
Gene symbols were almost universally provided across interpretations, although some interpretations do not 
have associated genes. 
 
For ​variants ​( ), we extracted the genomic coordinates (chromosome, start, stop) from eachSvariants, r ∈ R  
resource and created a unique set of those variants. JAX-CKB and OncoKB do not provide genomic 
coordinates for variants. When applicable, we split records by the appropriate delimiter to separate out multiple 
variants. For CGI, we also did minimal HGVS parsing for chr/start/stop when gDNA HGVS strings were 
provided. 
 
For ​diseases ​( ), we extracted the disease term from each knowledgebase and transformed itSdiseases, r ∈ R  
to lowercase text. PMKB represents diseases as a combination of tissue and tumor type, which we 
transformed to a compound string joined by a space (e.g., ​Tissue: Breast​ and ​Type: Adenocarcinoma​ became 
Disease:​ ​breast adenocarcinoma​). 
 
For ​drugs ​( ), we extracted the drug term from each knowledgebase and transformed it toSdrugs, r ∈ R  
lowercase text. As many interpretations contain more than one drug, we identified the delimiting character for 
each resource where multiple drugs are represented as a single string and split the string on the delimiter (e.g., 
the single string “​dabrafenib + trametinib​” was treated as the two strings “​dabrafenib​” and “​trametinib​”). 
 
We did not perform this analysis for ​evidence​ levels, as there is no shared meaning behind unharmonized 
evidence levels across resources (​Table 1​). 
 
The size of the set of unique values  was recorded in ​Supplementary Table 3​. For example,S|| e ∈ E, r ∈ R
|
|  
 (cell ​B3​ of ​Supplementary Table S3​) represents the 183 unique gene symbols observed in theS|| genes, cgi
|
|  
Cancer Genome Interpreter. 
Harmonized element counts: 
For each element , and each resource , we created a unique set of ​harmonized​ element ∈ Ee  ∈ Rr  
values observed in that resource, . These values were determined via the element harmonizationS′e, r  
routines specified in the previous ​Online methods ​sections. 
 
The sizes of the sets of unique values  were recorded in ​Supplementary Table 3​. ForS|| ′e ∈ E, r ∈ R
|
|  
example,  (cell ​C3​ of ​Supplementary Table 3​) represents the 182 unique gene symbols derivedS|| ′genes, cgi
|
|  
from the Cancer Genome Interpreter after harmonization. 
Summary of gains from harmonization: 
To measure the degree to which harmonization improved the consistency of observed terms across 
knowledgebases, we first calculated the total ​Terms Evaluated​. For each element , this consisted of e  
calculating both the total ​Terms Evaluated​ from both non-harmonized ( ) and harmonized ( ) valuesets: te  t′e  











For each element  ​we also recorded the total ​Unique Terms​ across the union of terms from all resources, bye  




























Finally, for each element  we calculate the ​Overlap​ as the percentage reduction of the total Terms Evaluatede  
to the total Unique Terms, for both the non-harmonized ( ) and harmonized ( ) valuesets: oe  o′e  
 ​and​ oe = 1 − teue o′e = 1 − t′eu′e  
 
 
